chemotherapy for soft tissue sarcoma

chemotherapy for soft tissue sarcoma - chemotherapy for soft tissue sarcoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013056

Enrollment

Registered

2014-02-04

Start date

2014-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

soft tissue sarcoma

Interventions

Chemotherapy was given by intra-arterial infusion using the reservoir, and consisted of cisplatin (3 mg/kg) in conjunction with the first, third, and fifth hyperthermia sessions and pinorubin (an adri

1 mg/kg) in conjunction with the second and fourth hyperthermia sessions. Two weeks after five sessions of RHC had been completed, patients received systemic chemotherapy (primarily ifosfamide), follo

Yamamoto Vinyter, Osaka, Japan). The temperature was measured by insertion of a hyperthermia needle into the scar tissue and insertion of a thermocouple thermometer (0.64-mm f) into the space. The obj

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically confirmed soft tissue sarcoma PS 0 to 2 Informed consent is obtained Inpatient

Exclusion criteria

Exclusion criteria: WBC<3000/ul Neutrophil <1500/ul Plt<75000/ul Hb < 7g/ul CCr< 60ml/min AST/ALT > 75IU/l(male),67.5IU/l(female) T-Bil > 3.0mg/dl No documented consent EF<50% allergy for planned drugs

Design outcomes

Primary

Measure	Time frame
local response	—

Secondary

Measure	Time frame
adverse effect, overall survival	—

Countries

Japan

Contacts

Public ContactSatoshi Yamada

Nagoya City University Graduate School of Medical Sciences Department of Orthopaedic Surgery

syamada@med.nagoya-cu.ac.jp052-853-8236

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026